Pfizer Inc. (NYSE: PFE) said Wednesday that the Food and Drug Administration announced an extension on its review of Prevnar 13, according to Associated Press.
The original deadline was Wednesday, but Pfizer says the agency has not completed its review of the children's pneumococcal vaccine. The pharmaceutical company did not indicate when the process might be complete. The FDA was originally scheduled to make a decision by Sept. 30, but decided to extend that review by three months.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Prevnar 13 is intended to reduce the risk of infection by 13 types of pneumococcal disease, which can cause ear infections, meningitis, pneumonia and blood infections. It is a newer version of a vaccine that has been on the market for nine years.
The vaccine is considered one of the most important products Pfizer acquired when it purchased rival Wyeth (NYSE: WYE) for $68 billion this year.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
